José A. López, MD
2010-01-01
Executive Vice-President for Research, Puget Sound Blood Center; Professor of Medicine and Biochemistry, University of Washington
In September 2009, hematology lost one of its legends, Eloise R. Giblett, MD. Dr. Giblett was a native and
life-long resident of the Pacific Northwest and spent her entire career at the Puget Sound Blood Center in
Seattle and affiliated with the University of Washington. Among her many accomplishments, Dr. Giblett
was one of the first to recognize polymorphism of human proteins. She identified a number of blood group
antigens, and she uncovered the association of purine metabolism with hereditary immunodeficiency syndromes.
Dr. Giblett was born in Tacoma, WA, in 1927. She was
known to all as Elo, an affectionate nickname given to her
by college friends. Her mother instilled within her a love of
music — a passion Elo carried throughout her life. Her primary
musical interest was the violin; most of her life she
played a violin given to her by her father when she was 11
years old, finally replacing it after she retired in 1987.
Dr. Giblett’s first academic interest was English; it was
only during college that she developed a keen interest in
science, first majoring in chemistry and then switching to
bacteriology (now known as microbiology) upon transferring
from Mills College in Oakland, CA, to the University of
Washington in Seattle. After her graduation during World
War II, she joined the Women Accepted for Volunteer
Emergency Service (WAVES), a division of the U.S. Navy,
“to do something positive for the war effort,” in her words.
Here, her bacteriology background held her in good stead,
landing her a job in the clinical laboratory of the U.S.
Naval Hospital in San Diego. While working at the hospital,
she found that it was possible to diagnose meningococcemia
on a stained blood smear, a finding that resulted in
her first scientific publication, in the American Journal of
Clinical Pathology.
Dr. Giblett then became one of only five women admitted
to the second entering class of the new University
of Washington School of Medicine. She graduated with
honors in 1951. She then entered a residency in internal
medicine and there met Dr. Clement Finch, the new chief of
the Hematology Division at the medical school. He invited
her to apply for a public health fellowship for postdoctoral
training in hematology, and she accepted. Her initial studies
were on the pathophysiology of hypersplenism and
its role in anemia, but two encounters during her fellowship
had much more profound influences on Dr. Giblett’s
scientific career: She met Dr. Arno Motulsky, who spurred
her interest in human genetics and would become a lifelong
friend, and she was offered a job in the King County
Central Blood Bank (now known as the Puget Sound Blood
Center) by its director, Dr. Richard Czajkowski. At the
time, Dr. Czajkowski was interested in having someone at
the Blood Bank trained in serology and genetics, and he
sent Elo to the lab of Dr. Patrick Mollison in the Medical
Research Council’s Blood Transfusion Research Unit in
London, where she was trained in serology and blood typing
by one of the preeminent experts of the day.
Upon returning to Seattle, she was hired as the associate
director of the Blood Bank and was appointed clinical
associate in medicine at the University of Washington. She
spent her entire career with the Blood Center, and it was
there that she made her major scientific contributions. Her
interest in blood groups blossomed into a broader interest
in genetic markers in human blood, which included not
only markers found on red blood cells, but also those found on other blood cells and in the plasma. This work
led to her identification of several blood group antigens.
In the process, she provided scientific evidence to refute
the then common practice of segregating collected
units of blood on the basis of the race of the donor. This
interest also led her to write a book, published in 1969 and
appropriately titled Genetic Markers in Human Blood. This
book was met with universal praise.
 |
| Dr. Giblett was an incredible human being,
a stellar scientist, and a visionary leader
who artfully guided the Puget Sound Blood
Center through one of its most trying
periods. While she will be greatly missed,
her legacy will live on. |
Also in keeping with her interest in genetic markers in
blood, Dr. Giblett began using a new method of starch gel
electrophoresis that had been developed by Dr. Oliver
Smithies to examine polymorphism in plasma proteins,
including haptoglobin and transferrin, and to study the
physiology of variants of the latter protein. She extended
the electrophoresis technique to the study of the activities
of polymorphic enzymes in both plasma and blood cells
and then used this technique clinically to examine genetic
markers in patients being considered for bone marrow
transplantation (BMT). One such polymorphic enzyme was adenosine deaminase (ADA), tested from red-cell lysates.
In 1972, while testing a child with severe combined immunodeficiency
(SCID) who was being considered for BMT,
Dr. Giblett and her colleagues noted that the child had no
ADA activity. The parents, who were related, had deficient
but not absent activity. Through sheer coincidence, she
heard about another SCID patient. She tested the patient
and found the patient to also be deficient in ADA activity.
The publication of these findings and the suggestion that
ADA deficiency could account for the immune deficiency
created great controversy in the field of immunology.
However, it was not long before a number of other SCID
patients were also shown to be deficient in the enzyme, and
ADA deficiency was established as the cause of the disease.
This connection between the purine salvage pathway and
immune deficiency prompted Dr. Giblett to investigate
other enzymes in the purine and pyrimidine metabolic
pathways in immune deficiency states, and this led to the
discovery of the purine nucleoside phosphorylase deficiency
as the cause of T-cell immunodeficiency.
These seminal discoveries, and many others, led to Dr.
Giblett’s election into the National Academy of Sciences in
1980. This honor came just one year after she was named
director of the Puget Sound Blood Center, an administrative
move that led her to close her laboratory. She
served as director until her retirement in 1987. Her tenure
spanned the period when AIDS was first recognized as a
disease and evidence emerged that it could be transmitted
by blood transfusion. She often mentioned her consternation
at the realization that the life-saving act of blood
transfusion, a procedure to which she had devoted much
of her career to making safer, could also transmit this
deadly disease.
In retirement, Dr. Giblett devoted a great deal of time to
her first love: music. She also remained a staunch supporter
of the Puget Sound Blood Center — its research
program, in particular.
On a personal note, Dr. Giblett left an indelible impression
on me when, as a trainee in hematology at the University of Washington, I had the opportunity to rotate on the
Blood Center’s Transfusion Service. The scientific rigor
with which she addressed clinical problems was extremely
impressive. This memory made it an easy choice for me
to return to the Puget Sound Blood Center in 2006 when
I was asked to direct its research program. Even before I
arrived in Seattle, Dr. Giblett contacted me to let me know
of her support for the program, and this encouragement
continued until the time of her death. Dr. Giblett was an
incredible human being, a stellar scientist, and a visionary
leader who artfully guided the Puget Sound Blood Center
through one of its most trying periods. While she will be
greatly missed, her legacy will live on.
back to top